D. Boral Capital Initiates Coverage on Plus Therapeutics (NASDAQ:PSTV)

D. Boral Capital assumed coverage on shares of Plus Therapeutics (NASDAQ:PSTV) in a report issued on Monday morning, Marketbeat.com reports. The firm issued a buy rating and a $9.00 price objective on the stock.

A number of other brokerages have also commented on PSTV. Ascendiant Capital Markets dropped their target price on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating on the stock in a research report on Monday, December 9th. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price on shares of Plus Therapeutics in a research report on Tuesday, November 26th.

Plus Therapeutics Stock Performance

Shares of PSTV stock opened at $0.51 on Monday. Plus Therapeutics has a fifty-two week low of $0.24 and a fifty-two week high of $2.67. The firm has a market capitalization of $3.01 million, a price-to-earnings ratio of -0.20 and a beta of 0.73. The stock’s 50-day simple moving average is $1.09 and its 200-day simple moving average is $1.24.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.